$AAT

American Assets Trust Executive Chairman Rady Buys Over $1 Million Shares. Does This Make AAT a Buy?

Ernest S. Rady, Executive Chairman of American Assets Trust (AAT), bought 50,000 shares at $21.65 each on Sept. 14, 2026. The company is a REIT with a $1.3B market cap, focusing on premium properties. AAT's TTM revenue is $439.7M with $20.7M net income. Rady's purchase follows a previous buy of nearly 600,000 shares.

Original reporting
Published Sep 25, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
American Assets Trust Executive Chairman Rady Buys Over $1 Million Shares. Does This Make AAT a Buy? — source image
Decision brief

The 30-second read

$AATBullishLow
01

Why it matters

The insider purchase provides a fresh data point for investors assessing AAT's valuation and potential upside.

02

Market read

AAT insider buying adds a modest bullish signal for the stock, but overall market impact is limited.

03

What to watch

The purchase represents a small fraction of total float and may not materially affect valuation.

Relevance 5/10Novelty 5/10Timing: post-market Sep 14, 2026

Background

American Assets Trust (AAT) is a fully integrated REIT focused on premium office, retail, and residential properties in high-barrier markets.

Company-level read

Ticker impact

$AATBullishMedium confidence
Context

Executive Chairman Ernest S. Rady purchased 50,000 AAT shares for $1.08M at $21.65 per share, disclosed via a Form 4 filing on Sept. 14, 2026.

Expected impact

Potential modest upside in the next few weeks as market digests the insider purchase.

Evidence & confidence

The purchase size is notable for a REIT of this market cap, but the amount is modest relative to total shares outstanding.

Market effects

May reinforce positive sentiment for the REIT sector, especially integrated office/retail landlords.

Limited to US REIT investors; no broader regional effect.

Minimal global impact; primarily a US REIT-specific event.

Counterpoint

Insider buying could be a personal liquidity move rather than a confidence signal.

Key entities

  • Ernest S. Rady

    Founder and Executive Chairman of American Assets Trust

Related articles

$AATMed

American Assets Trust Q2 Earnings Call Highlights

At La Jolla Commons Tower 3, which was 49% leased, proposals represented another 33% of the building. At One Beach Street in San Francisco, which was 35% leased, the company is converting remaining first- and second-floor availability into spec suites, with completion expected in the coming months.

$AATLow

American Assets Trust, Inc. Reports Second Quarter 2026 Financial Results

American Assets Trust, Inc. (AAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 a2q26supplemental.htm SUPPLEMENTAL INFORMATION Document SECOND QUARTER 2026 Supplemental Information Investor and Media Contact American Assets Trust, Inc. Robert F. Barton Executive Vice President and Chief Financial Officer 858-350-2607 American Assets Trust, Inc.'s P

Low

Nous Research $90M Raise: NVIDIA’s Dual Bet Reveals the Compute Landlord Strategy

NVIDIA is investing in both proprietary and open-source AI models, including a $90M Series B round for Nous Research, valuing it at $1.5B. Nous claims its Hermes 4.3 model outperforms GPT-4o in key metrics, but lacks independent verification. The company aims to compete with lower pricing, offering $0.30 per million tokens compared to competitors' higher rates. NVIDIA's strategy ensures its hardware remains central to AI infrastructure regardless of the winning model architecture.

$BHVNMed

Biohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian Markets

Biohaven (BHVN) has licensed its IgG degrader portfolio to Ono Pharma for Asian markets, including Japan and South Korea. The deal includes up to $100M in payments, with Biohaven retaining rights outside these regions. The portfolio, led by BHV-1300 in Phase 3 trials for Graves' disease, aims to treat autoimmune disorders. Biohaven's stock closed at $11.88, up 1.18% in pre-market trading.

$BAMed

NASA to pump hundreds of millions more tax dollars into troubled Boeing Starliner

NASA plans to invest $359 million more in Boeing's Starliner capsule for ISS missions, despite technical issues. The agency aims to send an unmanned Starliner to the ISS by late 2027, with a manned mission possible in 2028. The ISS is set to retire by 2030. SpaceX's Dragon Crew is noted as a cheaper, more reliable alternative. NASA insists on having two providers for ISS missions. Dr. Ken Kremer, a space expert, highlights the high stakes of maintaining a presence in low Earth orbit.